Drug intelligence / Profile preview

NKTR-119

Development stage: Preclinical
Lead developer: Nektar Therapeutics
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

NKTR-119 is a fixed-dose combination (FDC) product candidate consisting of naloxegol (NKTR-118) and an opioid analgesic. Naloxegol is a peripherally-acting mu-opioid receptor antagonist (PAMORA) developed using Nektar's proprietary PEGylation technology, which prevents the drug from crossing the blood-brain barrier. By combining naloxegol with an opioid, NKTR-119 aims to provide effective analgesia while proactively managing opioid-induced constipation (OIC) by blocking mu-opioid receptors in the gastrointestinal tract. The program was licensed to AstraZeneca by Nektar Therapeutics in 2009 as part of a broader agreement that included the development and commercialization of Movantik (naloxegol).

Other names: naloxegol + opioid combination

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on NKTR-119.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NKTR-119.

Explore the full profile